The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

The holiday season is a time for joy, family and exciting celebrations. However, for those individuals living with chronic illnesses, managing their health during this time can be an added ...

Chronic obstructive pulmonary disease (COPD), a significant yet often overlooked health issue in Malaysia due to low awareness and understanding, affects a considerable portion of the population, as ...

Fintel reports that on December 11, 2024, Citigroup downgraded their outlook for Pulmonx (NasdaqGS:LUNG) from Buy to Neutral.

The phase 1 clinical trial of APG333 is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers. It is expected to enroll approximately 32 ...

Chronic diseases don't discriminate when it comes to age. A new report from Sun Life points to more and more young Canadians being struck with life altering chronic physical conditions such as high ...

You may think you can avoid getting sick, but in Georgia, respiratory virus season is already upon us. Even if you lead an ...

Asthma, pneumonia and over 20 other conditions affecting the lungs and respiratory system are supported by PIP and ADP.

Growing population with respiratory diseases including chronic ailments is a key driver for the clinical demand ...

The editor’s pick for this issue is a review article discussing the promise of hyperpolarised xenon MRI, a non-invasive ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...